What is LOPJLB’s current signal on HOOK?

LOPJLB’s latest quantitative signal on HOOKIPA Pharma Inc. (HOOK) is SELL in a BULL regime. Signals are updated daily.

What market regime is HOOK in?

HOOKIPA Pharma Inc. (HOOK) is currently classified in the BULL HMM market regime on LOPJLB.

HOOKIPA Pharma Inc. (HOOK)

COMPARE

Healthcare · Biotechnology · OTC · US

$1.15+0.00%Close

SELLBULL · day 5

RANGE

DATA 2026-07-17

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONE

Key stats

Market cap: $14M
Beta: 0.77

P/E (TTM): -1.06

1W: +0.00%
1M: +0.00%

vs SPY 1W: -0.42%
vs SPY 1M: -2.06%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The companyâs immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting…

Employees: 82
Headquarters: US
Founded: 2019
Exchange: OTC
Sector: Healthcare
Industry: Biotechnology
Shares out: 12.5M
Float: 75.8%

hookipapharma.com ↗

Key executives

Malte Peters — Chief Executive Officer, President & Director

Mary Theresa Coelho — Executive Vice President, Chief Financial Officer & Director

Daniel D. Pinschewer — Co-Founder & Member of Scientific Advisory Board

SEC filings

EDGAR · CIK 17605420 · HOOK

Analyst consensus

Buy

Bullish555.6%

Neutral333.3%

Bearish111.1%

L $3.00Avg $3.00H $3.00

Target$3.00+160.87%

Last$1.15

FAQ

What is LOPJLB’s current signal on HOOK?: LOPJLB’s latest quantitative signal on HOOKIPA Pharma Inc. (HOOK) is SELL in a BULL regime. Signals are updated daily.
What market regime is HOOK in?: HOOKIPA Pharma Inc. (HOOK) is currently classified in the BULL HMM market regime on LOPJLB.
What does HOOKIPA Pharma Inc. (HOOK) do?: HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The companyâs immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic ca…

Key stats

Prediction markets

Company news

FAQ